Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2023-02-02 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Nytt patentbeviljande i USA för Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces a new patent grant in the USA from the USPTO for Episurf Medical concerning 3D-based joint damage assessment. It includes commentary from the COO and contact information. The final paragraph states: "Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is such information that Episurf Medical AB is obliged to disclose according to the EU Market Abuse Regulation). This structure—a brief, mandatory disclosure of a specific corporate event (patent grant) under MAR obligations—is characteristic of a general regulatory announcement that doesn't fit the more specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS). Since it is a mandatory regulatory disclosure that doesn't fit elsewhere, the most appropriate fallback category is Regulatory Filings (RNS). The document length (1805 chars) is short, but it is the primary disclosure, not an announcement *about* another report.
2023-02-02 Swedish
New US patent approval for Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces a specific, non-financial corporate event: the receipt of a new US patent approval from the USPTO. This is a material event disclosure. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a standard financial filing. It is a specific announcement regarding intellectual property/corporate development. Since there is no specific category for 'Patent Approval Announcement', and it is a material regulatory disclosure, the most appropriate general category is 'Regulatory Filings' (RNS), as it is a mandatory disclosure under EU Market Abuse Regulation mentioned at the end, and it doesn't fit the other specific categories like DIRS, DIV, or CAP. The document is short and serves as a direct announcement.
2023-02-02 English
Change in number of shares and votes in Episurf Medical
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly announces a 'Change in number of shares and votes in Episurf Medical' due to the exercise of warrants. It details the increase in B-shares and the total number of shares and votes. This directly relates to changes in the company's capital structure or share count. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for reporting changes in the total number of outstanding shares resulting from warrant conversion.
2022-12-30 English
Förändring av antalet aktier och röster i Episurf Medical
Share Issue/Capital Change Classification · 1% confidence The document is a short announcement titled "Förändring av antalet aktier och röster i Episurf Medical" (Change in the number of shares and votes in Episurf Medical). It explicitly states that shareholders exercised 256,877 stock options, leading to an increase in the total number of shares and votes. It concludes with a statement that this information is required to be made public according to financial instrument trading laws, dated December 30, 2022. This content directly relates to changes in the company's capital structure (share count and voting rights) due to option exercise, which aligns best with the 'Share Issue/Capital Change' definition (SHA). It is not a full report, a dividend notice, or an insider trade report.
2022-12-30 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for a specific holder ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension') involving a 'Sell' transaction, with specific dates (27/12/2022) and resulting share quantities and percentages. This structure, focusing on changes in significant ownership thresholds, directly corresponds to the definition of a Major Shareholding Notification. The filing type code for this is MRQ.
2022-12-28 English
Episurf Medical receives FDA 510(k) clearance for Episealer® Patellofemoral System
Regulatory Filings Classification · 1% confidence The document announces that Episurf Medical has received 510(k) clearance from the FDA for a new product system (Episealer® Patellofemoral System). This is a specific, material event announcement concerning regulatory approval and market access, rather than a routine periodic financial report (like 10-K or IR) or a general shareholder communication (like DEF 14A or AGM-R). It is a significant corporate event announcement. Since there is no specific category for 'Regulatory Approval Announcement,' and it is not a standard financial filing, it best fits the general 'Regulatory Filings' category (RNS) as a material regulatory update, or potentially 'Capital/Financing Update' (CAP) if the focus was on market entry funding, but the core news is the FDA clearance itself. Given the options, RNS serves as the best catch-all for significant, non-financial regulatory news that isn't a legal proceeding (LTR). However, since this is a major operational/regulatory milestone announcement, and not a standard periodic filing, RNS is the most appropriate fallback.
2022-12-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.